Cgm Dexcom denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for cgm dexcom are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Your Dexcom CGM as Not FDA-Approved

A "not FDA-approved" denial from Aetna typically means one of two things: (1) the plan believes the specific Dexcom model or the specific indication for which it was prescribed lacks FDA clearance or approval, or (2) the denial notice language conflates an FDA-approval question with an off-label use or non-covered indication question. In either case, this denial is almost always factually incorrect or misdirected for a current Dexcom product, because Dexcom's CGM systems carry FDA clearance for diabetes management.

The appeal strategy is straightforward: produce the FDA clearance documentation and link your specific clinical use to the cleared indication. If Aetna's real objection is an off-label or non-covered-indication issue, reframe the appeal to address medical necessity and guideline support for your specific use.

## Your Federal Appeal Rights

• Internal appeal: Submit within the deadline shown on your denial letter. Aetna must respond within 30 days (standard) or 72 hours (urgent/expedited).
• External review (ACA §2719 / ERISA §503): After a final internal denial, you are entitled to independent external review — generally within approximately four months of the final denial. The IRO applies objective standards and its decision is binding.
• Expedited review: Request it if your health situation is urgent.

## Documentation to Gather

1. FDA clearance documentation: The device's 510(k) clearance summary or FDA product page confirming clearance for diabetes management. This is publicly available on the FDA website and directly rebuts the denial rationale. 2. Product labeling: The current FDA-approved/cleared prescribing and device label listing the cleared indications. 3. Prescriber letter confirming on-label use: Your prescriber should confirm that the prescribed use matches the FDA-cleared indication and explain the clinical basis for prescribing. 4. Diagnosis and treatment records: Chart notes confirming your diabetes diagnosis and treatment context. 5. Applicable professional society guidance: Reference from your prescriber to the relevant guideline organization (e.g., American Diabetes Association) endorsing CGM for your profile.

## Criteria-Mapping Structure

Obtain Aetna's CGM medical policy and identify exactly which FDA-approval criterion triggered the denial. Respond point-by-point: confirm the cleared indication, confirm your use matches that indication, and attach the FDA clearance document as an exhibit. If the denial is actually about a coverage-policy restriction rather than genuine FDA status, redirect to medical necessity criteria and map your chart to each one.

This type of denial, when based on a factual mischaracterization of FDA status, resolves quickly once the correct documentation is in front of a medical reviewer. File promptly.